Table 6 Indicators to assess aggregate RACF-level concordance: benzodiazepines for sleep disturbance

1

Residents using benzodiazepines have documentation of individually targeted non-pharmacological management strategies for sleep disturbance that were trialled for an adequate period of time prior to commencing the benzodiazepine

GPS 26

2

Residents using benzodiazepines have documentation of individually targeted non-pharmacological management strategies to manage sleep disturbance that are currently in place

GPS 6

3

Residents using benzodiazepines have documentation of informed consent for use of the benzodiazepine

GPS 8

4

Residents using benzodiazepines have a documented date of next review for benzodiazepine treatment effectiveness

GPS 10

5

Residents using benzodiazepines have a current benzodiazepine adverse event monitoring protocol in place

GPS 28

6

Residents using benzodiazepines have used the current benzodiazepine for less than 2 weeks

GPS 26

7

Residents using benzodiazepines for more than 2 weeks are currently having the benzodiazepine dose tapered

GPS 29

8

Residents using benzodiazepines for more than 2 weeks and not currently tapering have documentation of a review of the harms and benefits of benzodiazepine continuation

CR 6